Evaluating Bezlotoxumab-Fidaxomicin Combination Therapy in Clostridioides Infection: A Single-Center Retrospective Study from Aichi Prefecture, Japan

<b>Background/Objectives:</b> <i>Clostridioides difficile</i> infection (CDI) poses a significant healthcare challenge, with recurrence rates reaching 30%, leading to substantial morbidity and costs. Fidaxomicin (FDX) and bezlotoxumab (BEZ) have shown potential in reducing re...

Full description

Bibliographic Details
Published in:Antibiotics
Main Authors: Jun Hirai, Nobuaki Mori, Yuki Hanai, Nobuhiro Asai, Mao Hagihara, Hiroshige Mikamo
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Subjects:
bezlotoxumab
fidaxomicin
combination therapy
<i>Clostridioides difficile</i>
recurrence
severe diarrhea
Online Access:https://www.mdpi.com/2079-6382/14/3/228

Internet

https://www.mdpi.com/2079-6382/14/3/228

Similar Items